Join Arrowhead Pharmaceuticals for Part 1 of the 2026 Summer Series of R&D Webinars focusing on the Company’s cardiometabolic pipeline, including plozasiran, zodasiran, and ARO-DIMER-PA. The webinar will feature a presentation by key opinion leader (KOL) Steven Nissen, M.D., (Heart and Vascular Institute at the Cleveland Clinic, Lerner College of Medicine), who will describe the current treatment landscape in mixed hyperlipidemia/ASCVD, the unmet medical need, and the opportunity that could be addressed by Arrowhead’s dual-functional siRNA (DIMER) technology. Arrowhead will also review prior clinical data and study design and anticipated timelines for its plozasiran and zodasiran Phase 3 programs.

A live question and answer session will follow the formal presentations.